Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1540-1551

  Bartee, Eric ^a   Chan, Winnie M ^a   Moreb, Jan S ^a   Cogle, Christopher R ^a   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Autologous hematopoietic stem cell transplantation; Ex vivo purging; Multiple myeloma; Myxoma virus; Viral oncolytics

Indexed keywords

ONCOLYTIC VIRUS; SYNDECAN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOGRAFT; BONE MARROW PURGING; CELL SPECIFICITY; CONTAMINATION; CONTROLLED STUDY; EX VIVO STUDY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; MYELOMA CELL; MYXOMA VIRUS; NONHUMAN; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIGENS, CD34; APOPTOSIS; CELLS, CULTURED; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; MYXOMA VIRUS; NEOPLASTIC STEM CELLS; ONCOLYTIC VIRUSES; RABBITS; RECURRENCE; SYNDECAN-1; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84866156501     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.04.004     Document Type: Article

References (46)

1. Ludwig H., Bolejack V., Crowley J., et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010, 28:1599-1605.
2. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
3. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
4. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
5. Björkstrand B., Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Semin Hematol 2007, 44:227-233.
6. Gertz M.A., Witzig T.E., Pineda A.A., Greipp P.R., Kyle R.A., Litzow M.R. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997, 19:337-342.
7. López-Pérez R., García-Sanz R., González D., et al. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000, 14:1493-1499.
8. Vogel W., Kopp H.G., Kanz L., Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005, 131:214-218.
9. Bashey A., Pérez W.S., Zhang M.J., et al. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant 2008, 14:1118-1124.
10. Gahrton G., Svensson H., Björkstrand B., et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999, 24:741-745.
11. Bensinger W.I., Demirer T., Buckner C.D., et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996, 18:527-531.
12. Alvarnas J.C., Forman S.J. Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled. Oncology (Williston Park) 2004, 18:867-876. discussion 876-878, 881, 884.
13. Motta M.R., Mangianti S., Rizzi S., et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Exp Hematol 1997, 25:1261-1269.
14. Strauss G., Westhoff M.A., Fischer-Posovszky P., et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ 2008, 15:332-343.
15. Spyridonidis A., Schmidt M., Bernhardt W., et al. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood 1998, 91:1820-1827.
16. Gee A., Moss T., Mansour V., et al. Large-scale immunomagnetic separation system for the removal of tumor cells from bone marrow. Prog Clin Biol Res 1992, 377:181-187.
17. Yang H., Robinson S.N., Nieto Y., et al. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res 2011, 71:5040-5049.
18. Ho J., Yang L., Banihashemi B., et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009, 43:223-228.
19. Bourhis J.H., Bouko Y., Koscielny S., et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007, 92:1083-1090.
20. Abonour R., Scott K.M., Kunkel L.A., et al. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 1998, 22:957-963.
21. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
22. Lemoli R.M., Fortuna A., Motta M.R., et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996, 87:1625-1634.
23. Rasmussen T., Björkstrand B., Andersen H., Gaarsdal E., Johnsen H.E. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol 2002, 30:82-88.
24. Voena C., Locatelli G., Castellino C., et al. Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. Br J Haematol 2002, 117:642-645.
25. Szczepek A.J., Bergsagel P.L., Axelsson L., Brown C.B., Belch A.R., Pilarski L.M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997, 89:1824-1833.
26. Takishita M., Kosaka M., Goto T., Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br J Haematol 1994, 87:735-742.
27. Kim M., Madlambayan G.J., Rahman M.M., et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009, 23:2313-2317.
28. Fenner F., Ratcliffe F.N. Myxomatosis 1965, Cambridge University Press, Cambridge, UK.
29. Stanford M.M., McFadden G. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 2007, 7:1415-1425.
30. Rahman M.M., Madlambayan G.J., Cogle C.R., McFadden G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev 2010, 21:169-175.
31. Johnston J.B., Barrett J.W., Chang W., et al. Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol 2003, 77:5877-5888.
32. Smallwood S.E., Rahman M.M., Smith D.W., McFadden G. Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol 2010, Chapter 14:Unit 14A 1.
33. Macen J.L., Upton C., Nation N., McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993, 195:348-363.
34. Madlambayan G., Bartee E., Kim M., et al. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding and not permissiveness to infection in vitro. Leuk Res 2012, 36:619-624.
35. Chung C.S., Hsiao J.C., Chang Y.S., Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998, 72:1577-1585.
36. Thirukkumaran C.M., Russell J.A., Stewart D.A., Morris D.G. Viral purging of haematological autografts: should we sneeze on the graft?. Bone Marrow Transplant 2007, 40:1-12.
37. Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Oncolytic virotherapy for hematological malignancies. Adv Virol. 2012;2012:1865512.
38. Lillo R., Ramírez M., Alvarez A., et al. Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Res 2002, 62:5013-5018.
39. Wagner L.M., Guichard S.M., Burger R.A., et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002, 62:5001-5007.
40. Garcia-Sanchez F., Pizzorno G., Fu S.Q., et al. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 1998, 92:672-682.
41. Kawa A., Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med 1987, 57:79-81.
42. Liu C., Russell S.J., Peng K.W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 2010, 18:1155-1164.
43. Peng K.W., Dogan A., Vrana J., et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009, 84:401-407.
44. Prestwich R.J., Errington F., Diaz R.M., et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009, 20:1119-1132.
45. Melcher A., Parato K., Rooney C.M., Bell J.C. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011, 19:1008-1016.
46. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005, 3:201-213.